Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports
The 8-month-old startup's 10-person team will join Anthropic's push into AI-powered drug discovery.
Anthropic has made a major move into the healthcare AI sector with the reported acquisition of biotech startup Coefficient Bio. According to sources cited by The Information and Eric Newcomer, the deal is valued at approximately $400 million and was structured as an all-stock transaction. The acquisition, which TechCrunch sources confirm has closed, represents a significant strategic investment for Anthropic as it builds out its capabilities in life sciences, following the launch of its specialized 'Claude for Life Sciences' tool last fall.
Coefficient Bio is a remarkably young company, founded just eight months ago by Samuel Stanton and Nathan C. Frey, both of whom have backgrounds in computational drug discovery at Genentech's Prescient Design unit. The startup has been operating in stealth mode, focusing on applying AI to streamline and improve the efficiency of drug discovery and broader biological research processes. As part of the deal, Coefficient Bio's compact team of around 10 employees is expected to be integrated into Anthropic's dedicated health and life science division, bringing valuable domain expertise to the AI company's ambitious healthcare initiatives.
- $400 million all-stock acquisition of 8-month-old stealth startup Coefficient Bio, as reported by The Information.
- Coefficient Bio's founders are ex-Genentech computational drug discovery experts, focusing on AI for biological research efficiency.
- The 10-person team joins Anthropic's health division, accelerating its 'Claude for Life Sciences' initiative announced in October 2023.
Why It Matters
This signals a major, capital-intensive push by leading AI labs into the high-stakes, high-reward domain of AI-driven drug discovery and healthcare.